Moving the agenda forward: The prevention and management of hepatitis c virus infection among people who inject drugs

Clinical Infectious Diseases

Volumn 57, Issue SUPPL.2, 2013, Pages

  Grebely, Jason ^a   Bruggmann, Philip ^b   Backmund, Markus ^c,d   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Arud Centres of Addiction Medicine   (Switzerland)

^c UNIVERSITY OF MUNICH   (Germany)

^d Praxiszentrum im Tal   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C VACCINE; NON PRESCRIPTION DRUG;

ANTIVIRAL THERAPY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MIXED INFECTION; PEER GROUP; PRIORITY JOURNAL; REVIEW; SCREENING; TREATMENT OUTCOME;

EID: 84880998115     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit264     Document Type: Review

References (24)

1. Hajarizadeh B, Grebely J, Dore GD. Epidemiology and natural history of hepatitis C virus infection [published online ahead of print 2 July 2013]. Nat Rev Gastroenterol Hepatol 2013; doi:10.1038/nrgastro.2013.107.
2. Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis 2011; 31: 331-9.
3. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2013; 56: 806-16.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
5. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
6. Iversen J, Grebely J, Topp L, et al. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011 [published online ahead of print 1 July 2013]. J Viral Hepat 2013; doi:10.1111/jvh.12129.
7. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16: 352-8.
8. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-83.
9. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitisCvirus infection in young adult injectors: using evidence toinform comprehensive prevention. Clin Infect Dis 2013; 57(Suppl 2):S32-8.
10. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent hepatitis C virus transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013; 57(Suppl 2):S39-45.
11. Cox A, Thomas DL. Hepatitis C virus vaccines among people who inject drugs. Clin Infect Dis 2013; 57(Suppl 2):S46-50.
12. Treloar C, Rance J, Backmund M. Barriers to hepatitis C virus care and stigmatization from a social perspective. Clin Infect Dis 2013; 57(Suppl 2):S51-5.
13. Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who use drugs: one size does not fit all. Clin Infect Dis 2013; 57(Suppl 2):S56-61.
14. Alavi M, Grebely J, Micallef M, et al. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. Clin Infect Dis 2013; 57(Suppl 2):S62-9.
15. Post J, Arain A, Lloyd A. Enhancing assessment and treatment of hepatitis C virus infection in prisons. Clin Infect Dis 2013; 57(Suppl 2): S70-4.
16. Crawford S, Bath N. Peer support models to enhance engagement in hepatitis C virus care. Clin Infect Dis 2013; 57(Suppl 2):S75-9.
17. Aspinall E, Corson S, Doyle J, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013; 57(Suppl 2):S80-9.
18. Hilsden RJ, Macphail G, Grebely J, et al. Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: A randomized controlled trial. Clin Infect Dis 2013; 57(Suppl 2):S90-6.
19. Reimer J, Schmidt CS, Schulte B, et al. Psychoeducation improves hepatitis C virus therapy outcomes in opioid-substituted patients: a controlled, prospective multicentre trial. Clin Infect Dis 2013; 57(Suppl 2):S97-104.
20. Grady B, Schinkel J, Thomas XV, Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis 2013; 57(Suppl 2):S105-10.
21. Schaefer MS, Sarkar R, Diez-Quevedo C. Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction. Clin Infect Dis 2013; 57(Suppl 2):S111-7.
22. Taylor LE, Swan T, Matthews GV. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral- based therapy. Clin Infect Dis 2013; 57(Suppl 2):S118-24.
23. Mauss S, Klinker H. Drug-drug interactions in the treatment of HCV among people who inject drugs. Clin Infect Dis 2013; 57(Suppl 2): S129-37.
24. Robaeys G, Grebely J, Mauss S, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis 2013; 57(Suppl 2):S135-43.